From the test tube to the patient, we're looking at new, inventive ways to move our product candidates efficiently through the development process in an effort to get new products into the clinic.

We have three monoclonal antibodies in human clinical trials and two in preclinical development, all based on the novel paradigm of specifically manipulating the relationship between T effector cells and T regulatory cells.